Loading
Loading…
Loading…
| # | Schedule | Awarded To | Bids | Value |
|---|---|---|---|---|
| 1 | Schedule 1 | Not yet disclosed by govt.Likely | 5 | - |
| 2 | Schedule 3 | Not yet disclosed by govt.Likely | 5 | - |
| 3 | Schedule 4 | WIZARD VENTURELikely | 1 | ₹2,516.40 |
| 4 | Schedule 5 | WIZARD VENTURELikely | 1 | ₹10,140 |
| 5 | Schedule 6 | WIZARD VENTURELikely | 1 | ₹3,390 |
Tender Value
₹86,314.50
EMD Value
Exempted
Closing Date
14 Aug 2026, 1:00 pmClosed
Budesonide Respirator Solution for use in Nebulizer (Q2) mg Tablet (Q1)
Ondansetron Injection (Q2) (V2) (Q2)
Amiodarone Injection (V2) (Q2) (Q2)
Sodium Phosphate Enema (Q2)
Glycopyrrolate Injection (Q2) Injection (Q2)
Ipratropium Bromide Respules (V2) (Q2) ( ( 3 3 ))
9507568
GEM/2026/B/7699348
Two Packet Bid
Budesonide Respirator Solution for use in Nebulizer,Anti TB Drugs - Isoniazid 300 mg Tablet,Ondanse
Ghaziabad, Uttar Pradesh
Item wise evaluation
PRODUCT
6 documents required · 6 mandatory
₹31
10%
| Item | Delivery Location | Qty | Delivery |
|---|---|---|---|
| Budesonide Respirator Solution for use in Nebulizer (Q2) mg Tablet (Q1) | - | - | - |
| Ondansetron Injection (Q2) (V2) (Q2) | - | - | - |
| Amiodarone Injection (V2) (Q2) (Q2) | - | - | - |
| Sodium Phosphate Enema (Q2) | - | - | - |
| Glycopyrrolate Injection (Q2) Injection (Q2) | - | - | - |
| Ipratropium Bromide Respules (V2) (Q2) ( ( 3 3 )) | - | - | - |
Exempted
Yes
11 Aug 2026
1 Aug 2026
14 Aug 2026
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_9507568.pdf
GEM_BID • 0.55 MB
isoniazid-300mg-pc-11-updated-feb-2021_2022-04-13-12-48-05_eeb1caa0dee44e836051b46bc7819ed1.pdf
GEM_OTHER • 0.33 MB
gtc.pdf
GEM_OTHER • 0.71 MB
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .